P
Pritha Bose
Researcher at Birla Institute of Technology, Mesra
Publications - 13
Citations - 184
Pritha Bose is an academic researcher from Birla Institute of Technology, Mesra. The author has contributed to research in topics: Liver X receptor & Protein kinase B. The author has an hindex of 5, co-authored 12 publications receiving 85 citations.
Papers
More filters
Journal ArticleDOI
Structure Based Multitargeted Molecular Docking Analysis of Selected Furanocoumarins against Breast Cancer.
TL;DR: The results confirm that Xanthotoxol has the best docking score for breast cancer followed by Bergapten, Angelicin, Psoralen and Isoimperatorin, and validate the molecular docking analysis.
Journal ArticleDOI
Bergapten inhibits liver carcinogenesis by modulating LXR/PI3K/Akt and IDOL/LDLR pathways
Shakti Prasad Pattanayak,Pritha Bose,Priyashree Sunita,Mohd Usman Mohd Siddique,Antonio Lapenna +4 more
TL;DR: Evidence is provided and the critical role of BeG in maintaining the lipid homeostasis is validated and justifies its anticancer potential against NDEA-induced HCC.
Journal ArticleDOI
Quercetin loaded folate targeted plasmonic silver nanoparticles for light activated chemo-photothermal therapy of DMBA induced breast cancer in Sprague Dawley rats
TL;DR: The development of a potential nanocarrier based on the pleiotropic function of plasmonic AgNPs may provide an efficient combined chemo-photothermal based strategy for the assassination of breast-cancer cells.
Journal ArticleDOI
Taxifolin binds with LXR (α & β) to attenuate DMBA-induced mammary carcinogenesis through mTOR/Maf-1/PTEN pathway.
Md. Wasimul Haque,Pritha Bose,Mohd Usman Mohd Siddique,Priyashree Sunita,Antonio Lapenna,Shakti Prasad Pattanayak +5 more
TL;DR: Taxifolin (TAX) modulated the energy regulation on DMBA-induced MC in SD-rats by significantly restoring the cancer-induced alterations in body weight, tumor growth and lipid, lipoproteins, lipid metabolizing enzymes and glycolytic enzymes.
Journal ArticleDOI
LC-MS characterized methanolic extract of zanthoxylum armatum possess anti-breast cancer activity through Nrf2-Keap1 pathway: An in-silico, in-vitro and in-vivo evaluation.
Roja Sahu,Rajiv K. Kar,Priyashree Sunita,Pritha Bose,Puja Kumari,Salona Bharti,Sharad Srivastava,Shakti Prasad Pattanayak,Shakti Prasad Pattanayak +8 more
TL;DR: The results exhibited anti-breast-cancer potential of MeZb through Nrf2-Keap1 pathway which may be due to the flavonoids, alkaloids and glycosides present in it.